SkinHealth Systems (SKIN) EBITDA (2020 - 2026)

SkinHealth Systems (SKIN) has 7 years of EBITDA data on file, last reported at -$6.9 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$6.9 million, up 22.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.9 million (up 95.18% YoY), and the FY2025 annual result was -$4.0 million, up 87.88% from the prior year.
• EBITDA rose to -$6.9 million in Q1 2026 per SKIN's latest filing, from -$7.8 million in the prior quarter.
• Over five years, EBITDA peaked at $31.3 million in Q1 2022 and troughed at -$74.9 million in Q3 2023.
• A 5-year average of -$6.0 million and a median of -$6.9 million in 2026 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2025: EBITDA sank 4262.9% in 2023, then jumped 3901.47% in 2025.
• A 5-year view of EBITDA shows it stood at $8.7 million in 2022, then slumped by 184.06% to -$7.3 million in 2023, then tumbled by 84.97% to -$13.6 million in 2024, then surged by 42.8% to -$7.8 million in 2025, then climbed by 11.01% to -$6.9 million in 2026.
• Business Quant data shows SKIN's EBITDA at -$6.9 million in Q1 2026, -$7.8 million in Q4 2025, and -$10.6 million in Q3 2025.